INV102 Asthma Product Discussed at the European Respiratory Society

SAN FRANCISCO, Sept. 22, 2009 — A symposium was held last week at the European Respiratory Society’s annual meeting in Vienna, Austria entitled “Beta-blockers may now be beneficial in asthma and COPD.”

“It is remarkable how far Inverseon’s asthma program has a…

MIQS Software Again Recognized by the Computerworld Honors Program; Wins Top Award

MIQS Recognized With Global Information Technology Award That Pays Tribute to Individuals and Organizations That Use Information Technology to Benefit Society

BOULDER, Colo., June 3, 2009 — MIQS, a Boulder-based electronic medical information software (EMR) company, has been recognized a…

Inverseon’s Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet

SAN FRANCISCO, Jan. 14, 2009 — Inverseon, Inc. (http://www.inverseon.com) announces the receipt of a notice of allowance from the United States Patent Office covering its oral product INV102 for asthma. Additionally, a comment highlighting Inverseon’s clinical asthma study was publ…

Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill

Groundbreaking Synergy Connect(TM) links health plan, physicians and community to assist individuals with chronic illness

TAMPA, Fla., Jan. 13, 2009 — Health Integrated, a pioneer in population health management, is actively helping people with chronic illnesses get the most medical and ps…